Actuate Therapeutics (ACTU), which is working on a treatment for pancreatic cancer, has filed for a proposed $50M initial public offering. The company didn’t disclose terms in its SEC filing, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback